ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
From "No Difference" to "Trending": misinterpretation of statistical analysis in animal studies.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frequentist approach, with its emphasis on statistical significance, remains predominant in animal research. However, the interpretation and reporting practices associated with this approach have not been evaluated in the context of in vivo pharmacology. In this study, 100 recent publications from 5 journals were analyzed. Of these, 61 studies (95% CI 51-71) either misinterpreted the results of hypothesis testing or used terminology that implied a gradation of p-values, rather than adhering to a binary distinction between significant and non-significant outcomes. Additionally, only 1 study (95% CI 0.03-5%) reported both effect sizes and confidence intervals, while 99 (95% CI 95-100%) relied exclusively on p-values for interpretation. Furthermore, none of the studies had a publicly available protocol or registration, precluding clear identification of primary outcomes, planned sample size calculations, and strategies for controlling family-wise error rates. These findings highlight the need for researchers in preclinical pharmacology to report effect sizes and appropriate precision metrics, such as confidence intervals, and to develop and register study protocols. This would support more comprehensive interpretation of results, improve methodological transparency, and reduce reliance on dichotomizing results alone, which can potentially inflate false positive findings.
Indexed as
Identifiers
40668415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.